Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.21, FiscalAI reports. The business had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $0.40 million.

Armata Pharmaceuticals Stock Up 1.4%

Shares of NYSEAMERICAN ARMP traded up $0.06 during mid-day trading on Wednesday, reaching $4.31. 126,433 shares of the company were exchanged, compared to its average volume of 92,798. Armata Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $16.34. The company’s 50 day moving average price is $5.77 and its 200 day moving average price is $8.15. The stock has a market capitalization of $158.22 million, a PE ratio of -0.55 and a beta of 1.30.

Get Armata Pharmaceuticals alerts:

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals during the 4th quarter valued at about $108,000. Millennium Management LLC purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth approximately $164,000. OMERS ADMINISTRATION Corp bought a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $177,000. Goldman Sachs Group Inc. bought a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $284,000. Finally, State Street Corp raised its stake in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares in the last quarter. Institutional investors own 3.57% of the company’s stock.

Analyst Ratings Changes

Separately, Zacks Research upgraded Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Read Our Latest Stock Analysis on ARMP

About Armata Pharmaceuticals

(Get Free Report)

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

See Also

• Five stocks we like better than Armata Pharmaceuticals
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.